Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05995964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorStudy sites: 95 to 97Primary completion date: Sep 21, 2026 to Oct 19, 2026 · Completion date: Dec 14, 2026 to Mar 8, 2027v25Show 2 more changesShow less
Primary completion date: Sep 21, 2026 to Oct 19, 2026
Completion date: Dec 14, 2026 to Mar 8, 2027
MinorStudy sites: 96 to 95Primary completion date: Jun 27, 2026 to Sep 21, 2026 · Completion date: Nov 14, 2026 to Dec 14, 2026 · Eligibility criteria expanded, about 12 words · 1 morev24Show 4 more changesShow less
Primary completion date: Jun 27, 2026 to Sep 21, 2026
MinorStudy sites: 73 to 96Primary completion date: Mar 26, 2026 to Jun 27, 2026 · Completion date: Sep 17, 2026 to Nov 14, 2026 · Eligibility criteria expanded, about 48 words · 1 morev23Show 4 more changesShow less
Primary completion date: Mar 26, 2026 to Jun 27, 2026
NotablePrimary completion date: Sep 4, 2025 to Mar 26, 2026Study sites: 55 to 59 · Completion date: Feb 26, 2026 to Sep 17, 2026 · Eligibility criteria expanded, about 39 words · 1 morev17Show 4 more changesShow less
Study sites: 55 to 59
Completion date: Feb 26, 2026 to Sep 17, 2026
Eligibility criteria expanded, about 39 words
Secondary endpoints: details revised at 7 of 7 entries
MinorStudy sites: 54 to 55Primary completion date: Feb 26, 2026 to Sep 4, 2025v16Show 1 more changeShow less
Primary completion date: Feb 26, 2026 to Sep 4, 2025
MinorStudy sites: 48 to 54v15
MinorStudy sites: 41 to 48Primary and study completion dates: Feb 13, 2026 to Feb 26, 2026 · Eligibility criteria shortened, about 1 wordv14Show 2 more changesShow less
Primary and study completion dates: Feb 13, 2026 to Feb 26, 2026
MinorStudy sites: 26 to 33Primary and study completion dates: Apr 6, 2026 to Feb 13, 2026 · Eligibility criteria revised · Secondary endpoints revised (7)v9Show 3 more changesShow less
Primary and study completion dates: Apr 6, 2026 to Feb 13, 2026
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 4 to 6v3Show 1 more changeShow less
Study sites: 4 to 6
MinorStudy sites: 1 to 4v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.
This study is seeking participants who:
* are 18 years of age or more.
* Were confirmed to have AD at least 6 months ago.
* Are not having an effective treatment result from medicines that are applied on skin for AD.
* Are considered by their doctors to have moderate to severe AD.
In Stage 1 of the study, participants will receive either PF-07275315 or PF-07264660 or placebo. Stage 1 is complete. In Stage 2 of the study participants will receive either PF-07275315 or placebo. In Stage 3 of the study participants who have received anti-inflammatory proteins, will receive either PF-07275315 or placebo. In Stage 4 of the study participants will receive either PF-07264660 or placebo. A placebo does not have any medicine in it but looks just like the medicines being studied.
PF-07275315 or PF-07264660 or placebo will be given as multiple shots in the clinic over the course of each Stage.
The experiences of people receiving PF-07275315 or PF-07264660 will be compared to people who do not. This will help determine if PF-07275315 and PF-07264660 are safe and effective.
Participants in Stages 1, 2 and 4 will be involved in this study for up to 40 weeks (10 months). Participants in Stage 3 will be involved in this study for up to 52 weeks (13 months).